US Stock MarketDetailed Quotes

CRBU Caribou Biosciences

Watchlist

3.980
-0.010-0.25%

Close Apr 23 16:00 ET

4.020
+0.040+1.01%

Post 19:59 ET

359.45MMarket Cap-2884P/E (TTM)

Caribou Biosciences Stock Forum

Trytosaveabit

Apr 16 18:31

Hmm?

$Caribou Biosciences(CRBU.US)$ Got a inverted hammer on the daily! Its wick actually broke above the downtrend continuation wedge! Its Really OS RSI 7 = 14.58! RSI 14 = 24.96! MACD Looks as if its fixing to GC? So lets just see how this turns out? Just thinking outloud

Trytosaveabit

Apr 5 04:07

Update

$Caribou Biosciences(CRBU.US)$ Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...

Moomoo AI

Feb 15 18:27

Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.

There's Reason For Concern Over Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Massive 25% Price Jump

Moomoo AI

Jan 4 22:17

Caribou Biosciences' revenue growth is promising but rising cash burn rate could concern investors. Raising more capital may result in shareholder dilution, making the situation risky.

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Aspiring_Millionaire

Dec 29, 2023 02:17

$Caribou Biosciences(CRBU.US)$ this stock 🥲

Trytosaveabit

Dec 13, 2023 17:31

Update

$Caribou Biosciences(CRBU.US)$ Caribou Biosciences (CRBU) said late Tuesday it has reached alignment with the US Food and Drug Administration with respect to the trial design of a planned phase 3 study of CB-010 for the treatment of patients with second-line relapsed or refractory large B cell lymphoma.
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...

Trytosaveabit

Nov 23, 2023 02:29

$Caribou Biosciences(CRBU.US)$ Bring on the volume! Another PR just hitting most outlets now! Hehehe

Trytosaveabit

Nov 23, 2023 02:18

News

$Caribou Biosciences(CRBU.US)$ Caribou Biosciences, Inc. Awarded FDA Orphan Designation Status For Allogeneic CAR-T Cells That Is Engineered To Express A Car Targeting The B Cell Maturation Antigen For The Treatment Of Multiple Myeloma

Moomoo AI

Nov 9, 2023 19:02

Despite forecasted negative growth, Caribou Biosciences' P/S ratio stays on par with the industry, signaling investor optimism. But, current high prices may not be long-lasting given the poor revenue outlook and the P/S ratio comparison.